Muscle changes in adults with obesity starting GLP-1 weight-loss medicines
Observes muscle mass and strength in obese adults without diabetes starting GLP-1 therapy.
Plain-language title generated from the registry record
Registry title: GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes
Key facts
- Where
- Istanbul, TürkiyeSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obesity but without diabetes who are currently using a GLP-1 receptor agonist. It studies muscle mass and strength at the start and at month 3.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Obesity, with BMI above 30 kg/m². No diabetes.
- Earlier treatment
- Must currently be using a GLP-1 receptor agonist. Must not be treated for major depressive disorder or take antidepressants.
Main reasons for not taking part
- Diabetes
- Chronic kidney failure, chronic liver disease, decompensated heart failure or cancer
- Pregnancy or breastfeeding
- Walking impairment
- Hearing, speech or cognitive impairment
Read by machine on 13 November 2026.
Where in Türkiye
- Kanuni Sultan Süleyman Training and Research HospitalIstanbul, TürkiyeContact: gülden ANATACATaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Istanbul Saglik Bilimleri University
- Trial code
- NCT07858864
- Record updated
- 8 October 2026
- Original description
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1/GIP agonists such as semaglutide and tirzepatide produce marked weight loss in people with obesity, with reported reductions of about 15-20%. Rapid weight loss may reduce not only fat mass but also lean body mass and skeletal muscle mass, raising concern about sarcopenia and sarcopenic obesity. Evidence in non-diabetic obese individuals is limited and inconsistent. This prospective descriptive study will assess muscle mass, muscle strength, physical performance and sarcopenia risk in non-diabetic obese adults starting GLP-1 RA therapy, at baseline and at month 3, and will examine how weight loss relates to changes in body composition.Read full original descriptionShow less
Evaluation of the Relationship Between GLP-1 Receptor Agonist Use and Sarcopenia in Non-Diabetic Obese Individuals: A Prospective Descriptive Study
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1/GIP agonists such as semaglutide and tirzepatide produce marked weight loss in people with obesity, with reported reductions of about 15-20%. Rapid weight loss may reduce not only fat mass but also lean body mass and skeletal muscle mass, raising concern about sarcopenia and sarcopenic obesity. Evidence in non-diabetic obese individuals is limited and inconsistent. This prospective descriptive study will assess muscle mass, muscle strength, physical performance and sarcopenia risk in non-diabetic obese adults starting GLP-1 RA therapy, at baseline and at month 3, and will examine how weight loss relates to changes in body composition.
Inclusion: Age 18 years or older; Diagnosis of obesity (BMI >30 kg/m²); Currently using a GLP-1 RA; No hearing, speech or cognitive impairment; Not receiving treatment for major depressive disorder and not using antidepressants; Verbal consent to participate.
Exclusion: Diagnosis of diabetes; History of chronic kidney failure, chronic liver disease, decompensated heart failure or malignancy; Walking impairment; Pregnancy or breastfeeding; Not meeting inclusion criteria or unwilling to participate.